Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Uterine Cervical Neoplasms"" wg kryterium: Temat


Tytuł :
Lymphoepithelioma-like carcinoma of uterine cervix: Preoperative diagnosis and course in three cases.
Autorzy :
Ikeda A; Department of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.; Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Abiko K; Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Emoto I; Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Ujita M; Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Takao Y; Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Konishi I; Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Pokaż więcej
Źródło :
The journal of obstetrics and gynaecology research [J Obstet Gynaecol Res] 2021 Nov; Vol. 47 (11), pp. 4093-4100. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Case Reports; Review
MeSH Terms :
Carcinoma, Squamous Cell*
Uterine Cervical Neoplasms*/diagnostic imaging
Uterine Cervical Neoplasms*/surgery
Biopsy ; Cervix Uteri/diagnostic imaging ; Cervix Uteri/surgery ; Female ; Humans ; Magnetic Resonance Imaging
Recenzja
Tytuł :
Self-collection for HPV screening: a game changer in the elimination of cervical cancer.
Autorzy :
Canfell K; The Daffodil Centre at the University of Sydney (Cancer Council NSW/University of Sydney), Sydney, NSW.
Smith MA; The Daffodil Centre at the University of Sydney (Cancer Council NSW/University of Sydney), Sydney, NSW.
Bateson DJ; Family Planning New South Wales, Sydney, NSW.; The University of Sydney, Sydney, NSW.
Pokaż więcej
Źródło :
The Medical journal of Australia [Med J Aust] 2021 Oct 18; Vol. 215 (8), pp. 347-348. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Papillomavirus Infections*/diagnosis
Papillomavirus Infections*/prevention & control
Uterine Cervical Neoplasms*/diagnosis
Uterine Cervical Neoplasms*/prevention & control
Early Detection of Cancer ; Female ; Humans ; Mass Screening ; Papillomaviridae
Opinia redakcyjna
Tytuł :
Association between IVIM parameters and treatment response in locally advanced squamous cell cervical cancer treated by chemoradiotherapy.
Autorzy :
Perucho JAU; Department of Diagnostic Radiology, Queen Mary Hospital, The University of Hong Kong, Room 406, Block K, Queen Mary Hospital, Pok Fu Lam Road, Hong Kong, People's Republic of China.
Wang M; Department of Diagnostic Radiology, Queen Mary Hospital, The University of Hong Kong, Room 406, Block K, Queen Mary Hospital, Pok Fu Lam Road, Hong Kong, People's Republic of China.
Vardhanabhuti V; Department of Diagnostic Radiology, Queen Mary Hospital, The University of Hong Kong, Room 406, Block K, Queen Mary Hospital, Pok Fu Lam Road, Hong Kong, People's Republic of China.
Tse KY; Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People's Republic of China.
Chan KKL; Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People's Republic of China.
Lee EYP; Department of Diagnostic Radiology, Queen Mary Hospital, The University of Hong Kong, Room 406, Block K, Queen Mary Hospital, Pok Fu Lam Road, Hong Kong, People's Republic of China. .
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2021 Oct; Vol. 31 (10), pp. 7845-7854. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
MeSH Terms :
Uterine Cervical Neoplasms*/diagnostic imaging
Uterine Cervical Neoplasms*/therapy
Adult ; Aged ; Aged, 80 and over ; Chemoradiotherapy ; Diffusion Magnetic Resonance Imaging ; Epithelial Cells ; Female ; Humans ; Middle Aged ; Motion ; Retrospective Studies
Czasopismo naukowe
Tytuł :
The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
Autorzy :
Keane A; Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.; Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Ng CW; Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Simms KT; Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
Nguyen D; Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
Woo YL; Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Saville M; VCS Foundation, Melbourne, Australia.
Canfell K; Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.; Prince of Wales Clinical School, Faculty of Medicine, UNSW, Sydney, Australia.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Dec 15; Vol. 149 (12), pp. 1997-2009. Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Disease Eradication/*organization & administration
Mass Screening/*organization & administration
Papillomavirus Infections/*prevention & control
Uterine Cervical Neoplasms/*prevention & control
Vaccination Coverage/*organization & administration
Alphapapillomavirus/isolation & purification ; Cervix Uteri/pathology ; Cervix Uteri/virology ; Cost-Benefit Analysis ; Disease Eradication/economics ; Female ; Humans ; Malaysia/epidemiology ; Mass Screening/economics ; Mass Screening/methods ; Papillomavirus Infections/diagnosis ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/virology ; Papillomavirus Vaccines/administration & dosage ; Uterine Cervical Neoplasms/diagnosis ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/virology ; Vaccination Coverage/economics
Czasopismo naukowe
Tytuł :
Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
Autorzy :
Hortlund M; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Mühr LSA; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Lagheden C; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Hjerpe A; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Dillner J; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Center for Cervical Cancer Prevention, Department of Pathology & Cancer Diagnostics, Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Dec 15; Vol. 149 (12), pp. 2083-2090. Date of Electronic Publication: 2021 Aug 31.
Typ publikacji :
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Alphapapillomavirus/*isolation & purification
Clinical Laboratory Services/*statistics & numerical data
Mass Screening/*statistics & numerical data
Papillomavirus Infections/*diagnosis
Uterine Cervical Neoplasms/*prevention & control
Adult ; Aged ; Cervix Uteri/pathology ; Cervix Uteri/virology ; Clinical Audit/statistics & numerical data ; Clinical Laboratory Services/organization & administration ; False Negative Reactions ; Female ; Humans ; Mass Screening/methods ; Mass Screening/standards ; Middle Aged ; Papillomavirus Infections/pathology ; Papillomavirus Infections/virology ; Sweden ; Triage/methods ; Triage/standards ; Triage/statistics & numerical data ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/virology ; Vaginal Smears/standards ; Vaginal Smears/statistics & numerical data ; Young Adult
Czasopismo naukowe
Tytuł :
Management of Cervical Dysplasia Using Office Loop Electrosurgical Excision Procedure.
Autorzy :
Ramírez SI; Department of Family and Community Medicine, Penn State Health Hershey Medical Center, 500 University Drive, Mail Code HP11, Hershey, PA, USA. Electronic address: .
Lutzkanin A; Department of Family and Community Medicine, Penn State Health Hershey Medical Center, 500 University Drive, Mail Code HP11, Hershey, PA, USA.
Pokaż więcej
Źródło :
Primary care [Prim Care] 2021 Dec; Vol. 48 (4), pp. 583-595. Date of Electronic Publication: 2021 Oct 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cervical Intraepithelial Neoplasia*/diagnosis
Cervical Intraepithelial Neoplasia*/surgery
Uterine Cervical Neoplasms*/diagnosis
Uterine Cervical Neoplasms*/surgery
Colposcopy ; Electrosurgery ; Female ; Humans ; Pregnancy ; Vaginal Smears
Czasopismo naukowe
Tytuł :
T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways.
Autorzy :
Liu H; Department of Gynecology, The Affiliated Hospital of Qingdao University , Qingdao, Shandong, P.R. China.; Department of Gynecology, The Third People's Hospital of Qingdao , Qingdao, Shandong, P.R. China.
Song M; Department of Gynecology Oncology, The Affiliated Central Hospital of Qingdao University , Qingdao, Shandong, P.R. China.
Sun X; Department of Gynecology, The Third People's Hospital of Qingdao , Qingdao, Shandong, P.R. China.
Zhang X; Department of Gynecology, The Third People's Hospital of Qingdao , Qingdao, Shandong, P.R. China.
Miao H; Department of Gynecology, The Third People's Hospital of Qingdao , Qingdao, Shandong, P.R. China.
Wang Y; Department of Gynecology, The Affiliated Hospital of Qingdao University , Qingdao, Shandong, P.R. China.
Pokaż więcej
Źródło :
Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 565-577.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Uterine Cervical Neoplasms*/genetics
Uterine Cervical Neoplasms*/metabolism
Cisplatin/*pharmacology
MicroRNAs/*genetics
T-Box Domain Proteins/*genetics
Antineoplastic Agents/pharmacology ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Female ; HeLa Cells ; Humans ; MAP Kinase Signaling System/drug effects ; MAP Kinase Signaling System/genetics ; MicroRNAs/metabolism ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; T-Box Domain Proteins/metabolism ; T-Box Domain Proteins/pharmacology
Czasopismo naukowe
Tytuł :
Lysine Acetyltransferase 2B predicts favorable prognosis and functions as anti-oncogene in cervical carcinoma.
Autorzy :
Li L; Department of Pathology, People's Hospital of Dongying District, Dongying City, Shandong Province, China.
Zhang J; Department of Pathology, People's Hospital of Dongying District, Dongying City, Shandong Province, China.
Cao S; Department of Gynecology, People's Hospital of Dongying District, Dongying City, Shandong Province, China.
Pokaż więcej
Źródło :
Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 2563-2575.
Typ publikacji :
Journal Article
MeSH Terms :
Oncogenes*
Uterine Cervical Neoplasms/*enzymology
Uterine Cervical Neoplasms/*genetics
p300-CBP Transcription Factors/*metabolism
Adult ; Cell Line, Tumor ; Cell Proliferation/genetics ; Disease Progression ; Epithelial-Mesenchymal Transition/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Neoplasm Metastasis ; Prognosis ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Uterine Cervical Neoplasms/pathology ; p300-CBP Transcription Factors/genetics
Czasopismo naukowe
Tytuł :
Circular RNA ZNF609 functions as a competing endogenous RNA in regulating E2F transcription factor 6 through competitively binding to microRNA-197-3p to promote the progression of cervical cancer progression.
Autorzy :
Gu Q; Department of Gynecology and Obstetrics, The Third Affiliated Hospital of Soochow University, Changzhou, P.R. China.
Hou W; Department of Gynecology and Obstetrics, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), Suzhou, P.R. China.
Shi L; Department of Gynecology and Obstetrics, The Third Affiliated Hospital of Soochow University, Changzhou, P.R. China.
Liu H; Department of Pathology, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, P.R. China.
Zhu Z; Department of Gynecology and Obstetrics, The Third Affiliated Hospital of Soochow University, Changzhou, P.R. China.
Ye W; Department of Gynecology and Obstetrics, The Third Affiliated Hospital of Soochow University, Changzhou, P.R. China.
Pokaż więcej
Źródło :
Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 927-936.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
E2F6 Transcription Factor*/genetics
E2F6 Transcription Factor*/metabolism
MicroRNAs*/genetics
MicroRNAs*/metabolism
RNA, Circular*/genetics
RNA, Circular*/metabolism
Uterine Cervical Neoplasms*/genetics
Uterine Cervical Neoplasms*/metabolism
Uterine Cervical Neoplasms*/pathology
Animals ; Cell Line, Tumor ; Cell Proliferation ; Disease Progression ; Female ; Gene Knockdown Techniques ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Real-Time Polymerase Chain Reaction
Czasopismo naukowe
Tytuł :
Identification and validation of potential mRNA- microRNA- long-noncoding RNA (mRNA-miRNA-lncRNA) prognostic signature for cervical cancer.
Autorzy :
Wang J; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Zhang C; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Pokaż więcej
Źródło :
Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 898-913.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
RNA, Messenger*/analysis
RNA, Messenger*/genetics
RNA, Messenger*/metabolism
RNA, Untranslated*/analysis
RNA, Untranslated*/genetics
RNA, Untranslated*/metabolism
Uterine Cervical Neoplasms*/genetics
Uterine Cervical Neoplasms*/metabolism
Uterine Cervical Neoplasms*/mortality
Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Gene Regulatory Networks/genetics ; Humans ; Prognosis
Czasopismo naukowe
Tytuł :
Symptomatic presentation of cervical cancer in emergency departments in California.
Autorzy :
Maguire FB; California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. .; California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, 1631 Alhambra Blvd., Suite 200, Sacramento, CA, 95816, USA. .
Cooley JJP; California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Morris CR; California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Parikh-Patel A; California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Kennedy VA; Department of Gynecology Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Keegan THM; California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.; Center for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA.
Pokaż więcej
Źródło :
Cancer causes & control : CCC [Cancer Causes Control] 2021 Dec; Vol. 32 (12), pp. 1411-1421. Date of Electronic Publication: 2021 Aug 23.
Typ publikacji :
Journal Article
MeSH Terms :
Uterine Cervical Neoplasms*/diagnosis
Uterine Cervical Neoplasms*/epidemiology
California/epidemiology ; Emergency Service, Hospital ; Female ; Humans ; Mass Screening ; Odds Ratio
Czasopismo naukowe
Tytuł :
Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data.
Autorzy :
Marcellusi A; Economic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy. .; Institute for Leadership and Management in Health, Kingston University London, London, UK. .
Mennini FS; Economic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy.; Institute for Leadership and Management in Health, Kingston University London, London, UK.
Sciattella P; Economic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy.
Favato G; Institute for Leadership and Management in Health, Kingston University London, London, UK.
Pokaż więcej
Źródło :
The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2021 Dec; Vol. 22 (9), pp. 1371-1379. Date of Electronic Publication: 2021 Jun 12.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Alphapapillomavirus*
Papillomavirus Vaccines*
Uterine Cervical Neoplasms*/epidemiology
Uterine Cervical Neoplasms*/prevention & control
Cohort Studies ; Female ; Humans ; Italy/epidemiology ; Male ; Papillomaviridae ; Retrospective Studies ; Vaccination
Czasopismo naukowe
Tytuł :
Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries.
Autorzy :
Partanen VM; Finnish Cancer Registry, Helsinki, Finland.
Dillner J; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Tropé A; Section for Cervical Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
Ágústsson ÁI; Cancer Detection Clinic, The Icelandic Cancer Society, Reykjavik, Iceland.
Pankakoski M; Finnish Cancer Registry, Helsinki, Finland.
Heinävaara S; Finnish Cancer Registry, Helsinki, Finland.
Sarkeala T; Finnish Cancer Registry, Helsinki, Finland.
Wang J; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Skare GB; Section for Cervical Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
Anttila A; Finnish Cancer Registry, Helsinki, Finland.
Lönnberg S; Finnish Cancer Registry, Helsinki, Finland.
Pokaż więcej
Źródło :
Journal of medical screening [J Med Screen] 2021 Dec; Vol. 28 (4), pp. 464-471. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Alphapapillomavirus*
Cervical Intraepithelial Neoplasia*
Papillomavirus Infections*/diagnosis
Papillomavirus Infections*/epidemiology
Uterine Cervical Neoplasms*/diagnosis
Uterine Cervical Neoplasms*/epidemiology
Colposcopy ; Cross-Sectional Studies ; Early Detection of Cancer ; Female ; Humans ; Papillomaviridae ; Pregnancy ; Vaginal Smears
Czasopismo naukowe
Tytuł :
Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan.
Autorzy :
Ohta T; Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, 990-9585, Japan.
Nagase S; Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, 990-9585, Japan. .
Okui Y; Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, 990-9585, Japan.
Enomoto T; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan.
Yamagami W; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Mikami M; Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.
Tokunaga H; Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ino K; Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
Ushijima K; Department of Obstetrics and Gynecology,, Kurume University School of Medicine, Kurume, Japan.
Shozu M; Department of Obstetrics and Gynecology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tashiro H; Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Mandai M; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Miyamoto S; Department of Obstetrics and Gynecology, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Morishige KI; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yoshida Y; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, Yoshida, Japan.
Yoshino K; Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Saito T; Gynecology Service, National Kyushu Cancer Center, Fukuoka, Japan.
Kobayashi E; Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kobayashi H; Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
Takekuma M; Department of Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Terai Y; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Fujii T; Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Aichi, Japan.
Kanao H; Department of Gynecologic Oncology, Cancer Institute Hospital, Tokyo, Japan.
Aoki D; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Katabuchi H; Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yaegashi N; Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2021 Dec; Vol. 26 (12), pp. 2318-2330. Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :
Journal Article
MeSH Terms :
Uterine Cervical Neoplasms*/pathology
Uterine Cervical Neoplasms*/surgery
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Hysterectomy ; Japan ; Middle Aged ; Minimally Invasive Surgical Procedures ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Performance of DNA methylation-based biomarkers in the cervical cancer screening program of northern Portugal: A feasibility study.
Autorzy :
Salta S; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Doctoral Program in Molecular Pathology and Genetics, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Porto, Portugal.
Maia-Moço L; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.
Estevão-Pereira H; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.
Sequeira JP; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Master Program in Oncology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Porto, Portugal.
Vieira R; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Bartosch C; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Porto, Portugal.
Petronilho S; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Porto, Portugal.
Monteiro P; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Sousa A; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.
Baldaque I; Virology Service, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Rodrigues J; Cancer Epidemiology Group, IPO Porto Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Centre of Mathematics (CMAT), University of Minho, Campus de Gualtar, Braga, Portugal.
Sousa H; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Virology Service, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Tavares F; Administração Regional de Saúde do Norte, Porto, Portugal.
Henrique R; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Porto, Portugal.
Jerónimo C; Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP) (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal.; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Porto, Portugal.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Dec 01; Vol. 149 (11), pp. 1916-1925. Date of Electronic Publication: 2021 Sep 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Methylation*
Early Detection of Cancer/*methods
Uterine Cervical Neoplasms/*diagnosis
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Cervical Intraepithelial Neoplasia/diagnosis ; Cervical Intraepithelial Neoplasia/epidemiology ; Cervical Intraepithelial Neoplasia/genetics ; Cervical Intraepithelial Neoplasia/pathology ; Feasibility Studies ; Female ; Humans ; Middle Aged ; Papillomaviridae/isolation & purification ; Papillomavirus Infections/diagnosis ; Papillomavirus Infections/genetics ; Papillomavirus Infections/pathology ; Portugal ; Promoter Regions, Genetic ; Sensitivity and Specificity ; Triage ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/pathology ; Young Adult
Czasopismo naukowe
Tytuł :
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Autorzy :
Colombo N; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Dubot C; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Lorusso D; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Caceres MV; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Hasegawa K; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Shapira-Frommer R; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Tewari KS; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Salman P; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Hoyos Usta E; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Yañez E; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Gümüş M; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Olivera Hurtado de Mendoza M; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Samouëlian V; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Castonguay V; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Arkhipov A; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Toker S; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Li K; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Keefe SM; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Monk BJ; From the University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome (D.L.) - both in Italy; Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France (C.D.); Instituto de Oncología Ángel H. Roffo, Buenos Aires (M.V.C.); Saitama Medical University International Medical Center, Hidaka, Japan (K.H.); Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); the University of California, Irvine, Orange (K.S.T.); Oncovida Cancer Center, Providencia (P.S.), and Universidad de la Frontera, Temuco (E.Y.) - both in Chile; IMAT (Instituto Médico de Alta Tecnología) Oncomedica, Monteria, Colombia (E.H.U.); Istanbul Medeniyet University Hospital, Istanbul, Turkey (M.G.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (M.O.H.M.); Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal (V.S.), and Centre Hospitalier Universitaire de Québec, Université Laval, Quebec (V.C.) - both in Quebec, Canada; the Medical Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow (A.A.); Merck, Kenilworth, NJ (S.T., K.L., S.M.K.); and Arizona Oncology (U.S. Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).
Pokaż więcej
Corporate Authors :
KEYNOTE-826 Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Nov 11; Vol. 385 (20), pp. 1856-1867. Date of Electronic Publication: 2021 Sep 18.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma/*drug therapy
Uterine Cervical Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Carcinoma/mortality ; Carcinoma/secondary ; Double-Blind Method ; Female ; Humans ; Intention to Treat Analysis ; Middle Aged ; Neoplasm Staging ; Patient Reported Outcome Measures ; Progression-Free Survival ; Survival Analysis ; Uterine Cervical Neoplasms/mortality ; Uterine Cervical Neoplasms/pathology
Czasopismo naukowe
Tytuł :
LncRNA AL592284.1 facilitates proliferation and metastasis of cervical cancer cells via miR-30a-5p/Vimentin/EMT axis.
Autorzy :
Zhang J; Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Liu HL; Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Liu JB; Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Zhang Y; Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Liu J; Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Li YH; Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. Electronic address: .
Pokaż więcej
Źródło :
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2021 Nov 05; Vol. 577, pp. 95-102. Date of Electronic Publication: 2021 Sep 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Cell Proliferation/*genetics
Organic Cation Transport Proteins/*genetics
RNA, Long Noncoding/*genetics
Uterine Cervical Neoplasms/*genetics
Vimentin/*genetics
Animals ; Cell Line, Tumor ; Female ; HEK293 Cells ; HeLa Cells ; Humans ; Male ; Mice, Inbred BALB C ; Mice, Nude ; MicroRNAs/genetics ; Neoplasm Metastasis ; Organic Cation Transport Proteins/metabolism ; RNA Interference ; Signal Transduction/genetics ; Uterine Cervical Neoplasms/metabolism ; Uterine Cervical Neoplasms/pathology ; Vimentin/metabolism
Czasopismo naukowe
Tytuł :
Achievement of live birth after overcoming two gynecological malignancies treated with radical trachelectomy and medroxyprogesterone acetate therapy.
Autorzy :
Tamauchi S; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Moriyama Y; Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Japan.
Suzuki S; Department of Gynecologic Oncology, Aichi Cancer Center, Nagoya, Japan.
Ikeda Y; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshikawa N; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kajiyama H; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Pokaż więcej
Źródło :
The journal of obstetrics and gynaecology research [J Obstet Gynaecol Res] 2021 Nov; Vol. 47 (11), pp. 4101-4105. Date of Electronic Publication: 2021 Aug 30.
Typ publikacji :
Case Reports
MeSH Terms :
Endometrial Neoplasms*/surgery
Fertility Preservation*
Trachelectomy*
Uterine Cervical Neoplasms*/drug therapy
Uterine Cervical Neoplasms*/surgery
Adult ; Antineoplastic Agents, Hormonal/therapeutic use ; Cesarean Section ; Female ; Humans ; Live Birth ; Medroxyprogesterone Acetate ; Pregnancy
Raport
Tytuł :
An endovaginal MRI array with a forward-looking coil for advanced gynecological cancer brachytherapy procedures: Design and initial results.
Autorzy :
Alipour A; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Radiology, Mount Sinai School of Medicine, New York, New York, USA.
Viswanathan AN; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Watkins RD; Department of Radiology, Stanford University, Stanford, California, USA.
Elahi H; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Loew W; Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Meyer E; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Morcos M; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Halperin HR; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Schmidt EJ; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Pokaż więcej
Źródło :
Medical physics [Med Phys] 2021 Nov; Vol. 48 (11), pp. 7283-7298. Date of Electronic Publication: 2021 Oct 08.
Typ publikacji :
Journal Article
MeSH Terms :
Brachytherapy*
Uterine Cervical Neoplasms*/diagnostic imaging
Uterine Cervical Neoplasms*/radiotherapy
Animals ; Equipment Design ; Female ; Humans ; Magnetic Resonance Imaging ; Phantoms, Imaging ; Signal-To-Noise Ratio ; Swine
Czasopismo naukowe
Tytuł :
Higher Dose to Organs at Risk: The Unintended Consequences of Intravenous Contrast Use in Computed Tomography Simulation for Cervical Cancer.
Autorzy :
Wang D; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yang B; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang W; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Liu X; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Liang Y; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Sun S; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Ma J; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhou B; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hu K; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhang F; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
Practical radiation oncology [Pract Radiat Oncol] 2021 Nov-Dec; Vol. 11 (6), pp. 534-543. Date of Electronic Publication: 2021 Aug 19.
Typ publikacji :
Journal Article
MeSH Terms :
Radiotherapy, Intensity-Modulated*
Uterine Cervical Neoplasms*/diagnostic imaging
Uterine Cervical Neoplasms*/radiotherapy
Female ; Humans ; Organs at Risk ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted ; Tomography, X-Ray Computed
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies